Chemistry and Pharmacology of Anticancer Drugs

  title={Chemistry and Pharmacology of Anticancer Drugs},
  author={David E. Thurston},
INTRODUCTION TO CANCER Terminology Metastases Diagnosis and Screening Formation of Cancer Cells (Tumorigenesis) Mechanisms of Genomic Damage Treatments Discovery of Anticancer Drugs and Preclinical Evaluation Accessibility of Drugs to Tumor Cells Achieving Selective Toxicity Limiting the Toxicity of Chemotherapeutic Agents Overview of Mechanisms of Action of Chemotherapeutic Agents Drug Resistance Combination Chemotherapy Use of Adjuvants Infertility Following Cancer Treatments ANTIMETABOLITES… 
Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch
Adverse reactions to 44 non-targeted and 33 targeted, frequently used, chemotherapeutic drugs are presented together with discussions of diagnosis, premedications, desensitizations and importance of understanding the mechanisms underlying the various drug-induced reactions.
Selective cytostatic and cytotoxic anticancer effects of bisfunctional agents: A strategy for the design of DNA binding agents.
This paper attempts to describe drugs in terms of the level of tumor cell selectivity which they possess to define the features of molecules that are essential for useful cytotoxicity.
Small Molecule Inhibitors
Before the biomedical community had had any understanding of the molecular mechanisms that drive tumorigenesis, the discovery of cancer chemotherapy exclusively focused on the development of novel
Hybrid anticancer 1,2-diazine derivatives with multiple mechanism of action. Part 3.
It is hypothesized that these molecules will exert their anticancer activity through multiple mechanisms of action: intercalating the DNA, inhibiting the topoisomerase enzymes and, destroying the DNA strands via electron transfer mechanism.
Kinases inhibitors in lung cancer: From benchside to bedside.
The current knowledge of all the chemical scaffolds, approved and/or investigational, utilized as inhibitors in lung cancer are revealed and the rationale of designing these along with possible interactions with their targets, biological data and possible problems associated with these inhibitors are explained.
Structural tuning of acridones for developing anticancer agents targeting dihydrofolate reductase.
The tumor growth inhibitory activity of substituted acridones is reported, with specificity to CCRF-CEM, MOLT-4 and SR cell lines of leukemia and SW-620, SF268, LOXIMVI, ACHN and MCF7 cancerous cells exhibiting GI50 in the nM range was observed.
Recent Advances in Oligonucleotide Therapeutics in Oncology
An overview of recent developments in the field of oligonucleotide therapeutics in oncology is provided, including results obtained in preclinical studies and clinical trials are encouraging, and associated challenges are discussed.
Evaluation of transcriptional cyclin dependent kinase inhibitors as potential cancer therapeutics
The combination of CDK9 and CDK1 inhibition results in effective induction of apoptosis in cancer cells and suggests that CDKI-71 has a great potential to be developed as an anti-cancer agent.
Proteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated Proteins.
Proteomics combined with pathway analysis provided information for an effective combined treatment approach overcoming drug resistance, and analysis of cell lines and tissues revealed potential prognostic biomarkers for ovarian cancer.
Synthesis of some novel thieno[3,2-d]pyrimidines as potential cytotoxic small molecules against breast cancer.
The cytotoxicity results from the study suggested that the synthesized molecules are potential antitumor agents and compound 4a was the most potent with an IC 50 2.04 nm.